Underutilised and underdosed? The role of hydroxycarbamide in sickle cell disease
Tracks
-
| Monday, April 20, 2026 |
| 8:00 AM - 9:30 AM |
| Hall 1C, Upper Level |
Details
This session will explore optimal dosing and use of hydroxycarbamide in sickle cell disease. Expert speakers will discuss remaining controversies including effects on fertility, dose escalation, and use in pregnancy and HbSC disease.
Speaker
Prof. Russell E. Ware
Director, Division Of Hematology
Cincinnati Children's Hospital
Hydroxyurea: Fact, Fiction, and Fantasy
8:00 AM - 8:40 AM
Prof. A. Yvonne Dei-Adomakoh
Haematologist
University of Ghana
Hydroxycarbamide as standard care for children and adults with sickle cell anaemia in a low-resource setting
8:40 AM - 9:00 AM
Prof. Valentine Brousse
Senior Consultant
Hôpital Universitaire Robert Debré
Hydroxycarbamide use and fertility issues
Dr Sara Stuart Smith
Haematology Consultant
King's College Hospital NHS Foundation Trust
Session Chair
